UnitedHealth Stock Jumps on Better-Than-Expected Medicare Advantage Rates. Here's Why the Rally Might Be Short-Lived

By David Jagielski, CPA – Apr 8, 2026 at 10:00AM ESTKey PointsMedicare Advantage rates will be rising by 2.48% next year, which is better than the flat changes proposed by the government earlier this year.The bigger issue for UnitedHealth, however, has been keeping costs down, and that may continue to be a problem.Shares of UnitedHealth Group (UNH 0.57%) jumped more than 9% on Tuesday on news that Medicare Advantage rates would be going up by 2.48% in 2027. Previously, the Trump administration suggested just a 0.09% change, which was far lower than analysts were expecting. While this is positive news for the health insurance giant, and the stock has been rallying, investors shouldn't assume it's off to the races. The company reports earnings in a few weeks, and the stock could end up giving back any gains it has generated up until then. Image source: Getty Images. UnitedHealth's biggest issue remains rising costs A big reason UnitedHealth's stock has been taking a beating in recent years hasn't been due to Medicare Advantage rates. Instead, there have been concerns over consistently high costs. Last year, its medical care ratio, which is a measure of how much of premiums are being used to cover medical claims, was up to 89%. It has normally been far lower in the past, closer to around 80%, and that difference can have a big impact on the bottom line. And while the boost to Medicare Advantage rates is encouraging and will help with the company's overall profits, investors shouldn't forget that it's still less than the 4% to 6% increase that analysts were expecting earlier this year. ExpandNYSE: UNHUnitedHealth GroupToday's Change(-0.57%) $-1.75Current Price$305.98Key Data PointsMarket Cap$278BDay's Range$304.83 - $312.9752wk Range$234.60 - $606.36Volume256KAvg Vol10MDividend Yield2.89% When the company reports earnings on April 21, investors could get a reality check and see that the healthcare stock, which is down more than 40% over the past 12 months, still has a long road ahead to recovery. This rally may not end up lasting for long. Read NextApr 9, 2026 •By Adria CiminoMeet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year.

Are They Still a Buy?Apr 8, 2026 •By Prosper Junior BakinyIs This Healthcare Stock a Millionaire Maker?Apr 8, 2026 •By Adria CiminoWhich of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?Apr 8, 2026 •By Eric VolkmanWhy Terns Pharmaceuticals Stock Rocked the Market in MarchApr 8, 2026 •By David Jagielski, CPA3 Absurdly Cheap Dividend Stocks to Buy in April 2026Apr 8, 2026 •By Prosper Junior BakinyThis Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic AreaAbout the AuthorDavid Jagielski, CPA, has been a contributing Motley Fool stock market analyst covering healthcare, consumer staples, consumer discretionary, and technology stocks since 2017. David has more than 10 years of experience in finance roles across businesses of different sizes and sectors. He holds a Certified Public Accountant designation in Canada.TMFdjagielski